FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna Amid Rising Cases
- Moderna Latest Study: mRNA Therapy for Treating T Cell-Mediated Autoimmune Diseases
- The Biosecure Act May Hurt Pharmaceutical Supply Chains
- Mosquito Elimination on Global Health: Unraveling the Claim of 700K Annual Deaths
- Intensive Blood Pressure Management to Below 140 mmHg Reduces Stroke Risk, Regardless of Medication Dosage
- GLP-1 Drugs: How Significant is Their Impact on Brain Health?
- Why Eel Sashimi Is Unsafe: Understanding the Risks of Consuming Raw Eel
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna Amid Rising Cases
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna Amid Rising Cases
On August 22, in response to a surge in COVID-19 cases, the U.S. Food and Drug Administration (FDA) approved updated COVID-19 vaccines from Pfizer and Moderna to better target the currently circulating strains of the virus.
Following the news, Pfizer’s stock dipped by about 1%, while Moderna’s stock fell by approximately 4.5% during U.S. trading hours.
According to the FDA, the new vaccines specifically target a variant known as KP.2, a third-generation subvariant of the Omicron JN.1 strain. KP.2 has shown a strong transmission advantage within the JN.1 lineage.
Data indicates that KP.2 was the predominant COVID-19 variant in May, with the World Health Organization (WHO) designating it as a “variant under monitoring” in early May. However, it now accounts for only about 3% of all infections in the U.S., suggesting that the FDA’s action may be somewhat delayed.
Nevertheless, both Pfizer and Moderna claim that their updated vaccines can elicit a stronger immune response against KP.2 and are also effective against other JN.1 subvariants still in circulation, such as KP.3 and LB.1.
Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research, stated, “Given the waning immunity in those who have previously contracted COVID-19 or have been vaccinated, we strongly recommend that eligible individuals consider getting the updated COVID-19 vaccine for better protection against the currently circulating variants.”
In June, the U.S. Centers for Disease Control and Prevention (CDC) recommended that everyone aged 6 months and older receive the latest COVID-19 vaccine and flu vaccine this year. The updated vaccines from Pfizer and Moderna are currently approved for individuals aged 12 and older, and are authorized for emergency use in children aged 6 months to 11 years.
Pfizer has announced that it will immediately begin distributing the new vaccine and expects it to be available in pharmacies, hospitals, and clinics across the U.S. in the coming days. Moderna also stated in a press release that it aims to roll out the product within the next few days.
Moderna’s CEO, Stéphane Bancel, emphasized, “Timely vaccination remains one of the best ways to protect people and prevent severe illness. We appreciate the FDA’s prompt review and encourage people to get the updated COVID-19 vaccine.”
The introduction of these updated vaccines offers some reassurance to Americans, as the COVID-19 situation in the U.S. worsens over the summer. Rising infection rates, hospital visits, and deaths have caused concern within the U.S. medical community.
CDC data reveals that nearly every state shows “very high” viral activity in wastewater samples. In the week ending August 10, the U.S. COVID-19 test positivity rate reached 18.3%, a significant increase from the previous month.
Dr. Anthony Fauci, former director of the National Institute of Allergy and Infectious Diseases, recently advised high-risk individuals to take the resurgence of COVID-19 seriously and consider wearing masks in crowded places. He noted that while people don’t need to stop their social activities or isolate, wearing a mask in crowded indoor spaces is the best preventive measure, especially for the elderly and those with underlying health conditions.
Despite long-standing recommendations from U.S. health officials that Americans receive an annual COVID-19 vaccine, many may choose to ignore this advice. A significant number of people believe that booster shots are no longer necessary and that COVID-19 is no longer a significant concern.
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna Amid Rising Cases
_________________________________
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.